GPx has developed an innovative platform that enables continuous, non-invasive monitoring of blood biomarkers, specifically through its flagship product, CardioID. This technology allows healthcare providers to track NT-proBNP levels in heart failure patients without the need for traditional blood draws, thereby enhancing patient comfort and compliance. The system utilizes a combination of digital and blood biomarkers collected from patients, which are then analyzed using proprietary predictive algorithms known as Bloodless Blood Tests. This approach not only streamlines the monitoring process but also provides actionable insights for clinicians, allowing for timely interventions based on real-time data.

The foundation of GPx's technology lies in its extensive database of paired blood and digital biomarkers, which facilitates longitudinal analysis and the development of predictive algorithms. By leveraging this unique dataset, GPx aims to identify correlations between non-invasive and traditional biomarkers, ultimately improving the management of chronic diseases. The company's commitment to rigorous data collection and automated validation processes ensures the reliability and clinical relevance of its algorithms. As GPx continues to expand its capabilities, it seeks partnerships to further enhance its research and application of Bloodless Blood Test technology in various therapeutic areas.

United States

General Prognostics (GPx) is revolutionizing remote chronic disease management with the world's first bloodless blood tests. Headquartered in Boston, MA, GPx is dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.

GPx

Company Details